Category Archives: Uncategorized

This paper describes the outcomes of secondary full-thickness macular holes (FTMHs) treated with topical therapy. Source: AAO

• Posted on: Aug 27 2020
• By: Saratoga Opthalmology
• Leave a response

This multicenter, prospective study assessed the prevalence of myelin oligodendrocyte glycoprotein antibodies (MOG-Ab) among adults with optic neuritis. Source: AAO

• Posted on: Aug 26 2020
• By: Saratoga Opthalmology
• Leave a response

Recordati Rare Diseases has announced FDA clearance of their cysteamine 0.37% eye drops (Cystadrops) for treating cystinosis-related corneal crystal deposits. Source: AAO

• Posted on: Aug 26 2020
• By: Saratoga Opthalmology
• Leave a response

This 2-year study compared the efficacy and safety of 3 concentrations of atropine eye drops to determine the optimal concentration for long-term myopia control. Source: AAO

• Posted on: Aug 24 2020
• By: Saratoga Opthalmology
• Leave a response

This week, surgeons get creative with a migrated Iluvien implant, Google unveils updates to its app for customers with visual impairments and researchers paint protective eyespots on a cow’s rear. Source: AAO

• Posted on: Aug 21 2020
• By: Saratoga Opthalmology
• Leave a response

This retrospective study compared the accuracy of IOL power calculation methods for myopic refractive targets. Source: AAO

• Posted on: Aug 20 2020
• By: Saratoga Opthalmology
• Leave a response

This is the first detailed, population-based study to describe the types of corneal diseases and the resulting visual impairments in a rural North Indian population. Source: AAO

• Posted on: Aug 19 2020
• By: Saratoga Opthalmology
• Leave a response

The FDA has approved satralizumab (Enspryng) for neuromyelitis optica spectrum disorder (NMOSD), making Genentech’s drug the first and only injectable treatment for the rare disease. Source: AAO

• Posted on: Aug 18 2020
• By: Saratoga Opthalmology
• Leave a response

This study investigates the characteristics of patients undergoing anti-VEGF injections for residual or recurrent diabetic macular edema (DME) after receiving a fluocinolone acetonide implant. Source: AAO

• Posted on: Aug 17 2020
• By: Saratoga Opthalmology
• Leave a response

This week, Regeneron shows off their second-quarter financial report, researchers discover a new treatment target for retinal diseases and OCT scans reveal an unexpected cause of a patient’s declining vision. Source: AAO

• Posted on: Aug 14 2020
• By: Saratoga Opthalmology
• Leave a response